Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03841331 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
A Phase 2 study, sponsored by Vyne Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 233
- Enrollment target
NCT03841331 is a Phase 2 study that has completed, run by Vyne Therapeutics. The registered enrollment target is 233 participants.
The verdict
NCT03841331, a Phase 2 study, has completed, sponsored by Vyne Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 233 participants
- Enrollment target
Study Summary
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
Interventions
- DRUG 5 mg Serlopitant Tablets
- DRUG Matching Placebo Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2019-01-22 |
| Est. Completion | 2020-01-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03841331
The ClinicalTrials.gov registry entry for NCT03841331 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 233 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vyne Therapeutics, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 5 mg Serlopitant Tablets is the first listed.
NCT03841331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03841331 about?
NCT03841331 is a clinical study titled "Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin". A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
What is the current status of trial NCT03841331?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 233 participants. The study started on 2019-01-22. Estimated completion is 2020-01-21.
What interventions are being tested in trial NCT03841331?
The interventions under investigation include: 5 mg Serlopitant Tablets (DRUG), Matching Placebo Tablets (DRUG).
Who is sponsoring clinical trial NCT03841331?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.